- Exchange: NASDAQ CM
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Dynavax Technologies Corp
+ Add to WatchlistDVAX:US
2.5100 USD 0.0200 0.80%As of 20:10:00 ET on 05/17/2013.
Snapshot for Dynavax Technologies Corp (DVAX)
| Open: | 2.4900 | Day's Range: | 2.4300 - 2.5500 | Volume: | 4,203,738 |
|---|---|---|---|---|---|
| Previous Close: | 2.5100 | 52wk Range: | 1.7400 - 5.1000 | 1-Yr Rtn: | -30.08% |
Key Statistics for DVAX
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.4100 |
| Est. EPS (USD) (12/2013) | -0.4100 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 459.06 |
| Shares Outstanding (M) | 182.89 |
| 30 Day Average Volume | 1,733,565 |
| Price/Book (mrq) | 4.6876 |
| Price/Sale (ttm) | 46.8623 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/01/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for DVAX
Company Profile & Key Executives for DVAX
Dynavax Technologies Corporation discovers, develops, and is seeking to commercialize products based on immunostimulatory sequences. The Company is developing products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using approaches that alter immune system responses in specific ways.
| Eddie GrayChief Executive Officer | J Tyler MartinPresident |
| Jennifer LewVP/CFO | Robert Lee CoffmanVP/Chief Scientific Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
DVAX News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page